Dermata Therapeutics Azioni (NASDAQ: DRMA)

Ultime notizie per Dermata Therapeutics (NASDAQ:DRMA) Azioni

Dermata Therapeutics

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

WIIM

ESTC

Elastic shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 guidance above estimates.

<p>Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) reported quarterly earnings of $0.31 per share. This is a 19.23 percent increase over earnings of $0.26 per share from the same period last year.  The company reported quarterly sales of $13.792 million which missed the analyst consensus estimate of $15.150 million by 8.96 percent.  This is a 24.27 percent increase over sales of $11.098 million the same period last year.</p>


Earnings

Earnings Misses

News

Pyxis Tankers Q3 2024 GAAP EPS $0.31 Up From $0.26 YoY, Sales $13.792M Miss $15.150M Estimate

Tapestry shares are trading higher after the company announced agreements for a $2 billion Accelerated Share Repurchase program.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.94</td>
<td align="right">0.18</td>
<td align="right">0.41</td>
<td>2.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.21</td>
<td align="right">0.32</td>
<td align="right">0.39</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">144.40</td>
<td align="right">0.37</td>
<td align="right">0.25</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">215.27</td>
<td align="right">0.27</td>
<td align="right">0.12</td>
<td>183</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.22</td>
<td align="right">0.05</td>
<td align="right">0.09</td>
<td>234.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">97.00</td>
<td align="right">-0.12</td>
<td align="right">-0.13</td>
<td>9.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.06</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>858</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">233.43</td>
<td align="right">-0.05</td>
<td align="right">-0.03</td>
<td>21.7K</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For November 22, 2024

<p>Targeting $200B Digital Grocery Market With Key Retailers Like Fareway Stores And Vroom Delivery</p>


PUBM

PubMatic Partners With DIGITS Agency To Monetize Digital Grocery Advertising Through Scalable AdTech Platform

<p>Wells Fargo  analyst Gary Mobley   initiates coverage on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Overweight rating and announces Price Target of $23.</p>


Price Target

Initiation

Analyst Ratings

ALGM

Wells Fargo Initiates Coverage On Allegro Microsystems with Overweight Rating, Announces Price Target of $23

<p>Leerink Partners  analyst Jeffrey La Rosa   initiates coverage on Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform rating and announces Price Target of $79.</p>


JANX

Leerink Partners Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $79

<p>Keybanc  analyst Tim Rezvan   maintains Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) with a Overweight and raises the price target from $165 to $205.</p>


GPOR

Keybanc Maintains Overweight on Gulfport Energy, Raises Price Target to $205

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Buy rating and announces Price Target of $130.</p>


Goldman Sachs Initiates Coverage On AECOM with Buy Rating, Announces Price Target of $130

<p>Wells Fargo  analyst Joe Quatrochi   initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight rating and announces Price Target of $155.</p>


Wells Fargo Initiates Coverage On ARM Holdings with Overweight Rating, Announces Price Target of $155

SBFM

Sunshine Biopharma shares are trading higher after its Nora Pharma subsidiary launched Ursodiol, a generic version of URSO DS.

<p>Keybanc  analyst Steve Barger   maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Overweight and raises the price target from $205 to $215.</p>


Keybanc Maintains Overweight on AMETEK, Raises Price Target to $215

<p>Confirmed By Nasdaq Listing Qualifications On November 21, 2024</p>


NDRA

ENDRA Life Sciences Regains Compliance With Nasdaq Minimum Bid Price Rule

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Sell rating and announces Price Target of $445.</p>


Goldman Sachs Initiates Coverage On EMCOR Group with Sell Rating, Announces Price Target of $445

<p>UBS  analyst David Vogt   initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Neutral rating and announces Price Target of $95.</p>


UBS Initiates Coverage On Celestica with Neutral Rating, Announces Price Target of $95

<p>Goldman Sachs  analyst Ben Andrews   initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $320.</p>


FLUT

Goldman Sachs Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $320

Nano Labs Unveils Second-Generation V Series Crypto Mining Products With 5x Power Efficiency Boost And Enhanced Stability, Featuring Advanced Cuckoo 3.0 Chips In V2, V2H, And V2X Models

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Nuzee&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/"><strong>NUZE</strong></a>) stock is heading higher on Wednesday alongside heavy pre-market trading of the coffee machine company&rsquo;s shares.</p>



<p>This has more than 8 million shares of NUZE stock changing hands as of this writing. That&rsquo;s well above its daily average trading volume of about 575,000 shares. Investors will also keep in mind that its <a href="https://finance.yahoo.com/quote/NUZE/key-statistics/">float is 560,520 shares</a>.</p>



<p>All of this activity comes without any clear news from Nuzee. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage that would cause NUZE stock to rally today.</p>



<p>One thing investors will note is that NUZE is a penny stock. That comes from its prior closing price of $1.03 per share and its market capitalization of just $2.459 million.</p>



<h2>Why That Matters to NUZE Stock</h2>



<p>Being a penny stock comes with the risk of extra volatility. That makes sense as retail and day traders sometimes pump up these shares.</p>



<p>However, that also means the stock isn&rsquo;t likely to maintain its increased price. Once those traders sell their shares for profits, NUZE is likely to come back down from this high. Traders will want to weigh that potential when considering a stake in Nuzee.</p>



<p>NUZE stock is up 133% as of Wednesday morning.</p>



<p>Investors will want to keep reading for more of the most recent stock market stories!</p>



<p>We have all of the hottest stock market news ready to go on Wednesday! Among that is what has shares of <strong>Dermata Therapeutics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready at the links below!</p>



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/07/dear-sofi-stock-fans-mark-your-calendars-for-july-30-2/">Dear SOFI Stock Fans, Mark Your Calendars for July 30</a></li>
</ul><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">Why Is Nuzee (NUZE) Stock Up 133% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Why Is Nuzee (NUZE) Stock Up 133% Today?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!</p>



<p>Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Psyence Biomedical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/"><strong>PBM</strong></a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li><strong>Tivic Health Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/"><strong>TIVC</strong></a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li><strong>BloomZ </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li><strong>Cero Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/"><strong>CERO</strong></a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li><strong>Viking Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/"><strong>VKTX</strong></a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li><strong>VS Media</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/"><strong>VSME</strong></a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li><strong>Indivior </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/"><strong>INDV</strong></a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li><strong>Signing Day Sports</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/"><strong>SGN</strong></a>) shares are jumping more than 14% without any clear news this morning.</li>



<li><strong>Davis Commodities</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/"><strong>DTCK</strong></a>) stock is getting a 14% boost on Thursday morning.</li>



<li><strong>Stellus Capital Investment</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/"><strong>SCM</strong></a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>2U </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/"><strong>TWOU</strong></a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li><strong>Edwards Lifesciences</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/"><strong>EW</strong></a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li><strong>Selina Hospitality</strong>  (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/"><strong>SLNA</strong></a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li><strong>MaxLinear </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/"><strong>MXL</strong></a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li><strong>Fangdd Network</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/"><strong>DUO</strong></a>) stock is sliding more than 17% after a rally yesterday.</li>



<li><strong>IF Bancorp</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/"><strong>IROQ</strong></a>) shares are falling over 16% despite a lack of news this morning.</li>



<li><strong>Regencell Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/"><strong>RGC</strong></a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li><strong>Hoth Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/"><strong>HOTH</strong></a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li><strong>Nuzee </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/"><strong>NUZE</strong></a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li><strong>Dermata Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

VSee Health, Dermata Therapeutics, and Exicure, Inc. are the 3 Penny Stocks to watch on August 6, based on&nbsp;TipRanks' Penny Stock Screener tool...

3 Penny Stocks to Watch Now, 8/6/24

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Dermata Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Dermata Therapeutics reported earnings per share of -$4.18. This was below the analyst estimate for EPS of -$3.79.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/drma-stock-earnings-dermata-therapeutics-for-q2-of-2024/">DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

Dermata Therapeutics GAAP EPS of -$4.18

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>What do you call a growth stock that isn&rsquo;t growing any more?</p>



<p>The answers are many. You can call it a disappointment. A drain on your portfolio. A bad investment. Any of these are true of F-rated <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a>, as evaluated by the Portfolio Grader.</p>



<p>And in today&rsquo;s market, you can ill-afford to a bad investment. The market is in some turmoil this summer.</p>



<p>I know it&rsquo;s only temporary, but times like these are when some investors start to panic and make bad decisions &ndash; particularly when they see their hard-earned money start to drain away in a sell-off.</p>



<p>It can be tempting to take a flyer on a stock in a weakened position. In fact, sometimes that can be a very good decision to buy strong growth stocks at a discount. </p>



<p>You also need to be able to identify those opportunities rather than F-rated growth stocks that have little, if any, hope of bouncing back in the near future.</p>



<p>F-rated growth stocks are typically characterized by weak fundamentals, poor financial health, and inconsistent performance, which can lead to substantial losses. </p>



<p>They can also be volatile, with extreme price fluctuations driven by speculation rather than solid financial performance.</p>



<p>We&rsquo;re using the Portfolio Grader today to help us identify the worst growth stocks available today, based on factors such as analyst sentiment, growth history, earnings reports and momentum. All of these names are on my list of stocks to avoid today.</p>



<h2>Nio (NIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/nio1600-2-300x169.png" alt="NIO logo, sign atop of North American headquarters and global software development center in Silicon Valley. NIO is Chinese electric autonomous vehicles manufacturer"><div>Source: Michael Vi / Shutterstock.com</div></div><p>Chinese EV maker&nbsp;<strong>Nio</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/"><strong>NIO</strong></a>) has to be one of the most disappointing electric vehicle stocks. I had high hopes at one point that Nio&rsquo;s battery-swapping technology would be a difference-maker and would allow Nio to become a dominant EV company in Asia.</p>



<p>But not any longer. It&rsquo;s hard to have faith in any company that used to trade for $60 a share and now is down closer to $3.</p>



<p>Nio has had a lot of starts and stops. It&rsquo;s getting ready to launch its new mass market EV brand, Onvo, with the first Onvo model, the L60, to debut in September. </p>



<p>There&rsquo;s also a lot of competition in the Chinese EV space, and Nio will likely be shut out by cars that are selling at a lower price point than the L60, which has a pre-order price of $30,460.</p>



<p>Nio reported delivering 20,498 vehicles in July, which is the third consecutive month that the company delivered more than 20,000 vehicles. But the market is obviously not impressed, as NIO stock is down 60% this year and 33% in the last three months.</p>



<p>Nio gets a &ldquo;D&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.</p>



<h2>FuelCell Energy (FCEL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/fcel1600-1-300x169.png" alt="Person holding cellphone with logo of US fuel cell company FuelCell Energy Inc. (FCEL) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>FuelCell Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcel-stock-quote/"><strong>FCEL</strong></a>) manufactures, operates and services Direct Fuel Cell power plants that produce hydrogen. For providers who are looking for a green energy solution, hydrogen is appealing because it produces zero carbon emissions.</p>



<p>It has the potential to be highly efficient in fuel cells by providing more energy per unit of fuel compared to traditional combustion engines.</p>



<p>The company has more than 100 fuel cell plants in operation around the world and has generated more than 15.8 million megawatt-hours of power.</p>



<p>But just because it sounds like a good idea doesn&rsquo;t make something a good investment. Second-quarter revenue was $22.4 million, down from $38.3 million a year ago. FuelCell Energy posted a loss of $7.1 million, or 7 cents per share.</p>



<p>Obviously, growth is not in the cards for FuelCell, despite its efforts to expand its business in the Koren market. There are much better opportunities for investors.</p>



<p>FCEL stock is down 71% so far this year. It gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.</p>



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/muln1600-2-300x169.png" alt="In this photo illustration, the Mullen Technologies (MULN) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div><p>Tell me if you&rsquo;ve heard this one before &ndash; <strong>Mullen Automotive</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/"><strong>MULN</strong></a>) stock is below $1 per share again.</p>



<p>This is a sad repeat of a story that&rsquo;s plagued the EV company for the last several months. Mullen actually enacted three reverse stock splits last year, including a 1-for-100 split in December, in a desperate ploy to keep the stock price over $1 and maintain compliance with Nasdaq listing rules.</p>



<p>The cumulative ratio of all these stock splits are 1-for 22,500. And more dilution is on the way, as Mullen announced plans to resell up to <a href="https://www.sec.gov/Archives/edgar/data/1499961/000182912624005041/mullenautomotive_s1.htm#a_004">85 million shares</a> on the conversion of notes and exercise of warrants. </p>



<p>When Mullen made the announcement there were only 24.85 million shares outstanding. Mullen acknowledged that the transactions could lead to &ldquo;substantial diminution to the value of shares of common stock held by our current stockholders.&rdquo;</p>



<p>Mullen only invoiced for 362 vehicles in six months ending March 31. It posted a net loss of $235 million in that period, while invoicing only $16.3 million.</p>



<p>Mullen stock is trying to make deals to turn things around, but another reverse stock split seems inevitable. MULN stock is down 95% this year and earns a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.</p>



<h2>SolarEdge Technologies (SEDG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/sedg-stock-1-300x169.jpg" alt="SolarEdge logo on phone with American flag background. SEDG stock"><div>Source: IgorGolovniov / Shutterstock.com</div></div><p><strong>SolarEdge Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/"><strong>SEDG</strong></a>) is another green power company. It makes power optimizers and inverters to help solar panels operate more efficiently.</p>



<p>The primary issue for SolarEdge, however, isn&rsquo;t the quality of its work or the efficiency of its equipment. It&rsquo;s the overall economy that makes solar power investment less appealing right now.</p>



<p>Interest rates remain inflated and the Fed seems stubbornly opposed to providing relief. Solar panels are a significant expense and fewer people are willing to borrow money to convert their homes to solar as long as interest rates remain high.</p>



<p><a href="https://investors.solaredge.com/static-files/ab9d304f-bfed-4320-95b0-bc5bdee6d0b2">Revenue in the second quarter</a> was $265.4 million, down 73% from a year ago. The company posted a net loss of $130.8 million, a year after posting a profit of $119.5 million.</p>



<p>If interest rates drop, then SolarEdge may return to its growth ways. But that&rsquo;s not happening now. SEDG stock is down 75% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.</p>



<h2>2U (TWOU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/twou1600-300x169.png" alt="Person holding smartphone with logo of American educational technology company 2U Inc. on screen in front of web page. Focus on phone display. Unmodified photo. TWOU stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>2U</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/"><strong>TWOU</strong></a>) is an educational technology company that works with nonprofit colleges and universities to create online degree and nondegree programs. But it hasn&rsquo;t been a great business model, as many colleges are able to offer online courses without outside help.</p>



<p>The Maryland-based company filed for Chapter 11 bankruptcy in July, after reporting more than $1 billion in debt in the first quarter and only $125 million in cash. </p>



<p>2U announced a deal with&nbsp;<a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">lenders to cut its debt by 50%</a>, while extending the duration of its loan. It will also receive an additional $110 million in capital from lenders.</p>



<p>TWOU stock is down 95% this year and is approaching $1 per share despite instituting a 1-for-30 reverse stock split this summer. The stock is one to avoid.</p>



<p>TWOU gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.</p>



<h2>Dermata Therapeutics (DRMA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p><strong>Dermata Therapeutics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a>) is a clinical-stage biotechnology company based in California. Dermata is focused on creating treatments for skin conditions and diseases.</p>



<p>Its lead drug candidate, DMT310, is in Phase 3 trials for the treatment of acne, rosacea, and psoriasis. It is a once-weekly topical product made from naturally sourced freshwater sponges. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis.</p>



<p>The company says it&rsquo;s enrolled more than 50% of its patients in the trial and hopes to complete enrollment in the second half the year.</p>



<p>The challenge with biotech companies, of course, is that research and development is expensive and companies don&rsquo;t have a revenue stream during the long testing process. Companies are reliant on raising money and acquiring partners during the testing until they can bring a drug to market and start gaining revenue.</p>



<p>For the second quarter, Demata reported having $4.9 million in cash on hand, down from $7.4 million in the previous quarter. The company spent $4.8 million during the quarter on research and company operations, and raised $2.3 million from selling warrants.</p>



<p>The company believes it has sufficient funds to operate into the fourth quarter, so it will have to raise additional money if its going to continue its work.</p>



<p>DRMA stock is down 75% this year and gets a &ldquo;C&rdquo; rating for growth and an &ldquo;F&rdquo; rating overall in the Portfolio Grader.</p>



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/plug1600-9-300x169.png" alt="Mobile phone with logo of American hydrogen fuel cell company Plug Power Inc. in front of business website. Focus on center of phone display. Unmodified photo. PLUG stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Plug Power</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/plug-stock-quote/"><strong>PLUG</strong></a></span>) had another bad day this week, as the company posted another disappointing earnings report that missed analysts&rsquo; expectations for both revenue and earnings per share.</p>



<p>The company, which is attempting to build the first commercially viable market for hydrogen fuel cell technology, posted revenue of $143.3 million for the second quarter, down from $260.1 million a year ago. </p>



<p>The company also posted another <a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Power-Announces-Key-Developments-and-Strategic-Milestones-in-Second-Quarter-2024/default.aspx">big operating loss</a> of $244.6 million slightly worse than the $233.8 million loss that Plug sustained in the second quarter of 2023. Overall, Plug&rsquo;s loss came in at 36 cents per share. </p>



<p>Even though Plug has deployed more than 69,000 fuel cell systems and more than 250 fueling stations, I wouldn&rsquo;t call what its doing a viable business. At some point you need to start making money, and Plug isn&rsquo;t anywhere close.</p>



<p>Plug is projecting full-year revenue this year to be between $825 million and $925 million. A year ago it posted revenue of $891 million, so it appears growth this year will be challenging at best.</p>



<p>PLUG stock  is down 54% this year and gets &ldquo;F&rdquo; ratings for growth and overall in the Portfolio Grader.</p>



<p><em>On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/market360/2024/08/7-f-rated-growth-stocks-to-avoid-like-the-plague-in-august-2024/">7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024

Dermata Therapeutics prices $3.5M equity offering

Dermata Therapeutics files to sell 5.87M shares of common stock for holders

Dermata Therapeutics GAAP EPS of -$2.04 misses by $0.68

Dermata Therapeutics GAAP EPS of -$2.04

BLMZ

CERO

DRMA

DRMAW

DTCK

FCEL

HOTH

INDV

IROQ

MULN

NUZE

PLUG

SEDG

SLNA

TIVC

TWOU

VKTX

VSEE

VSME

XCUR

Press Releases

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Biotech

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Events

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Comments

Dermata Therapeutics

Notizie

Ultime notizie per Dermata Therapeutics (NASDAQ:DRMA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO